TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06021210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir Pill
Description: Letermovir is the world's first and only new drug approved for the prevention of CMV infection. In 2017, it was approved by the U.S. Food and Drug Administration (FDA) for the prevention of CMV infection and disease in CMV-seropositive adult recipients (R+) of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It was approved in China on December 31, 2021.
Study: NCT04358471

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal AAVCAGsCD59
Description: AAVCAGsCD59 is administered as an intravitreal injection in the enrolled eye

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal AAVCAGsCD59
Description: AAVCAGsCD59 is administered as an intravitreal injection in the enrolled eye

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Intravitreal Sham Injection
Description: Sham injection mimics a real injection in the enrolled eye
Study: NCT06215729

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine rehabilitation treatment
Description: The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation treatment
Description: The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional cognitive training
Description: including Memory training, attention training, and executive function training were conducted 2-5 times per week, lasting for 30-60 minutes each session, based on the patient's condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted Cognitive Function Training
Description: Based on the patient's cognitive impairment assessment results, the training content includes Attention game training, Executive function program training, Logical reasoning training, Agility training, Memory training. The training is conducted seven days a week, once a day, for a duration of 30-45 minutes per session
Study: NCT05087238

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT
Description: Cognitive Behavior Therapy for PVC-specific anxiety education, in-vivo exposure, interoceptive exposure, behavioral activation, relapse prevention
Study: NCT06277128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 3g
Description: Acute treatment phase: WS016, oral, 3g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 3g, once daily for 12 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 6g
Description: Acute treatment phase: WS016, oral, 6g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 6g, once daily for 12 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 12g
Description: Acute treatment phase: WS016, oral, 12g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 12g, once daily for 12 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Acute treatment phase: Matching Placebo, oral, three times a day for 48 hours; Maintenance treatment phase: Matching Placebo, oral, once daily for 12 days.
Study: NCT05145556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolarygoscopy
Description: In a randomised order we evaluate the first pass success rate of the tracheal tube into the trachea.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional laryngoscopy
Description: In a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
Study: NCT05635266

Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen sample
Description: The study may require a tissue collection and/or a participant survey for participation. Most tissue collected will come from a blood draw; up to 100mL for the health condition group, 60mL for the exceptive condition group, and up to 180mL for the control group (if determined safe for the participant). Participant surveys may involve participant reported outcomes (PROs) or custom participant surveys.

Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen sample
Description: The study may require a tissue collection and/or a participant survey for participation. Most tissue collected will come from a blood draw; up to 100mL for the health condition group, 60mL for the exceptive condition group, and up to 180mL for the control group (if determined safe for the participant). Participant surveys may involve participant reported outcomes (PROs) or custom participant surveys.

Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen sample
Description: The study may require a tissue collection and/or a participant survey for participation. Most tissue collected will come from a blood draw; up to 100mL for the health condition group, 60mL for the exceptive condition group, and up to 180mL for the control group (if determined safe for the participant). Participant surveys may involve participant reported outcomes (PROs) or custom participant surveys.
Study: NCT05414162

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Hematooncology patients under CAR T-cell therapy will receive 3 MRI examinations: at baseline, within 2 weeks of start of CAR T-cell therapy, and at 6 months follow-up.
Study: NCT05496192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab/rHuPH20
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT05961644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine Subcutaneous Injection
Description: Cladribine subcutaneous injection, 10 mg daily, for 2-3 consecutive days (depending on individual dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Chloride Injection Sodium
Description: 0.9% sodium chloride injected subcutaneously, 10 ml daily, for 2-3 consecutive days
Study: NCT05899010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone 600mg daily
Description: If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone 800mg daily
Description: If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
Study: NCT03937830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: 1,150 mg flat dose every 21 days, starting on day 1 of cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: 1,150 mg flat dose every 21 days, starting on day 1 of cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: 1,150 mg flat dose every 21 days, starting on day 1 of cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin-Eluting Beads
Description: used for TACE (only in patients with HCC BCLC stage B)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE with Doxorubicin-Eluting Beads (only in patients with HCC BCLC stage B) on Cycle 2. More TACE can be done if clinically necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 7.5 mg/kg dose every 21 days, starting on day 1 of cycle 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 7.5 mg/kg dose every 21 days, starting on day 1 of cycle 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 7.5 mg/kg dose every 21 days, starting on day 1 of cycle 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 300, 150 or 75 mg once on day 1 of cycle 1
Study: NCT05891613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 20 ml of 0.25% Bupivacaine (50 mg) with 20 ml of injectable saline (total of 40 cc) as a subcutaneous infiltration along the inframammary fold incision on one breast
Study: NCT06282562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Description: Individualized High-Intensity Interval Training (HIIT) program with two exercise sessions per week for 12 weeks. The exercise sessions will be conducted on a stationary bike, with intensity tailored to each participant's maximum exercise capacity.
Study: NCT05891613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 20 ml of 0.25% Bupivacaine (50 mg) with 20 ml of injectable saline (total of 40 cc) as a subcutaneous infiltration along the inframammary fold incision on one breast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: 20 ml of Liposomal (Exparel) Bupivacaine (266 mg/20 ml) on the contralateral breast
Study: NCT04668144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cangrelor
Description: Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The total infusion will last 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The total infusion will last 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel will be used in line with FDA recommendations using a 60mg LD followed by a 10mg daily maintenance dose started 24 hours after LD administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel will be used in line with FDA recommendations using a 60mg LD followed by a 10mg daily maintenance dose started 24 hours after LD administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel will be used in line with FDA recommendations using a 60mg LD followed by a 10mg daily maintenance dose started 24 hours after LD administration
Study: NCT06117683

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ADULT Sotair Device
Description: Sotair® device employs a flow limiting and pressure control valve mechanism.
Study: NCT06108141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resident Education And Counseling on Household Firearm Safety
Description: An intervention that includes a self-directed online curriculum and virtual reality simulations, designed to teach firearm screening and counseling among clinicians.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified American Academy of Pediatrics Safer
Description: An intervention that includes a self-directed online curriculum.
Study: NCT06200155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Given by PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Niacin
Description: Given by PO
Study: NCT05873803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR1802 injection
Description: 150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
Study: NCT05306444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-418
Description: Intravenous (IV) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-418
Description: Intravenous (IV) administration
Study: NCT06004063

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN)
Description: Given by Nasogastric Tube

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care parenteral nutrition (PN)
Description: Given by PO or Given by IV (vein)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care parenteral nutrition (PN)
Description: Given by PO or Given by IV (vein)
Study: NCT05429021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM-BCP-01
Description: Single dose of IMM-BCP-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM-BCP-01
Description: Single dose of IMM-BCP-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM-BCP-01
Description: Single dose of IMM-BCP-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM-BCP-01
Description: Single dose of IMM-BCP-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of IMM-BCP-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of IMM-BCP-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of IMM-BCP-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of IMM-BCP-01
Study: NCT06477354

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACEMg
Description: Softgel capsules
Study: NCT06085729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Description: Given by Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given by IV (vein)
Study: NCT05033145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZVUDINE
Description: AZVUDINE 5 tablets QD + standard treatment, for up to 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZVUDINE placebo
Description: 5 tablets QD + standard treatment, for up to 14 days
Study: NCT04685681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hiking challenge
Description: The main intervention of interest is the provision of free access to a local hiking challenge (which is provided following baseline assessments in the experimental group and after the conclusion of the study in the control group; $20 value). If participants choose to sign up for the free hiking challenge, they receive a list of local hikes/nature walks, accompanying maps, scavenger-hunt-like activities (finding a certain landmark on each hike), and the opportunity to earn prizes and engage with other hikers on social media.
Study: NCT06085729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by IV (vein)
Study: NCT06085092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open weighing
Description: The open-weighing intervention aims to challenge beliefs about weight gain. The study coordinator (SC) will explain open weighing, discuss any concerns you have about your weight, and construct a weight graph with the number of weeks on the x-axis and weight in pounds on the y-axis. The SC will help identify beliefs about gaining weight, which will be written on a Feared Outcomes Form. The SC will ask you to predict your weight, mark the weight prediction on the graph, weigh you on a standing scale, record your weight, and discuss your responses to seeing your weight, including any reasons for a difference between your predicted and actual weight. Each week, the SC will graph your actual and predicted weights over time and discuss anything that you are learning from this process. The SC will ask you to complete the Feared Outcomes Form once per day over the next week, review it each week, and talk to you about what you are learning from this process.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Blind weighing
Description: The blind weighing intervention aims to help you see self-weighing as an eating disorder symptom that you should stop, and that weight is not important to your identity or self-esteem. To do this, the study coordinator will explain why blind weighing might be helpful. You will then be asked to step backwards on a standing scale. The study coordinator will record your weight but will not share your weight information with you. The study coordinator will discourage you from thinking or talking about your weight.
Study: NCT06094933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Anger Reduction Intervention (MARI)
Description: This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will download the MARI app and be instructed to complete at least 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Condition (HED)
Description: This is a mobile application that delivers videos with psychoeducation about healthy habits and selfcare for general wellness. Participants will download the HED app and be instructed to use it at least 5 times a week for a period of 4 weeks.
Study: NCT03937830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 300, 150 or 75 mg once on day 1 of cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 300, 150 or 75 mg once on day 1 of cycle 1
Study: NCT06428253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HMM1-022
Description: intradermal injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HMM1-022
Description: intradermal injection
Study: NCT06570785

Intervention type: DEVICE
Intervention: Intra-Operative Positioning System (IOPS)
Description: This medical device provides surgeons with 3D visualization for increased surgical precision while reducing the use of contrast dye and radiation exposure for patients and healthcare professionals alike. IOPS provides 3D electromagnetic navigation of interventional devices as an adjunct to fluoroscopy. During the intervention, the IOPS devices can be visualized with on-screen image guidance. The console is operated by a technician under a physician's instruction. The IOPS guidewires and catheters can be used together or combined with off-the-shelf 0.035-inch catheters and guidewires, as needed.

Intervention type: DEVICE
Intervention: Conventional group
Description: This group will be treated using standardised materials (wires, catheters) during EVAR.
Study: NCT04685681

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity list
Description: The control group will receive a list of CDC-recommended activities following the baseline survey and will receive the hiking challenge as a delayed intervention following post-test.
Study: NCT04891692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimaWell 120MTRS system
Description: Medium-frequency electrotherapy device that delivers current via up to 12 channels. The device also provides heat therapy up to 40°C.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimaWell 120MTRS system
Description: Medium-frequency electrotherapy device that delivers current via up to 12 channels. The device also provides heat therapy up to 40°C.
Study: NCT05898932

Intervention type: OTHER
Intervention: Medical Management
Description: Participants will be managing condition with medication

Intervention type: OTHER
Intervention: Surgical Management
Description: Participants will be managing condition with a surgery
Study: NCT06533332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERX-315
Description: Drug administered intravenously twice a week at increasing dose levels, with starting dose of 0.4mg/kg.
Study: NCT05349136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synchronous telerehabilitation group
Description: This group will receive Action Observation Treatment with a synchronous telerehabilitation method. Children in this group will be applied Action Observation Treatment 5 days a week for 3 weeks, for a total of 15 sessions under the supervision of a physiotherapist via videoconferencing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asynchronous telerehabilitation group
Description: This group will receive Action Observation Treatment with an asynchronous telerehabilitation method. Children in this group will be applied Action Observation Treatment 5 days a week for 3 weeks, for a total of 15 sessions under parental supervision.
Study: NCT05252988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib orally once daily for 13 cycles, unless patient discontinues earlier.
Study: NCT05883267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: PICO model neo 2 VR glasses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vocal-guided affective imagery
Description: Audio via telephone